BIIB
Undervalued by 34.7% based on the discounted cash flow analysis.
Market cap | $27.69 Billion |
---|---|
Enterprise Value | $33.58 Billion |
Dividend Yield | $0.0 (0.0%) |
Earnings per Share | $7.97 |
Beta | 0.0 |
Outstanding Shares | 145,360,798 |
Avg 30 Day Volume | 1,131,387 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 23.85 |
---|---|
PEG | -43.66 |
Price to Sales | 3.01 |
Price to Book Ratio | 2.0 |
Enterprise Value to Revenue | 3.41 |
Enterprise Value to EBIT | 18.34 |
Enterprise Value to Net Income | 28 |
Total Debt to Enterprise | 0.21 |
Debt to Equity | 0.47 |
No data
No data
At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therape...